Translating diagnostic innovation and governed clinical AI into clinical impact
Translyx Limited brings advanced diagnostics, authorised digital pathology AI, and Privexa-built protected AI workflows to New Zealand and Oceania — helping clinicians, laboratories, healthcare providers, and research teams adopt innovation with privacy, governance, and clinical discipline.
Our purpose
The global diagnostics market is transforming. New Zealand healthcare needs a specialist bridge.
Rapid advances across antimicrobial resistance, sepsis diagnostics, point-of-care testing, digital pathology AI, and precision medicine are reshaping clinical decision-making worldwide. The challenge for New Zealand and Oceania is access — ensuring clinicians and laboratories can adopt these technologies in a way that is practical, evidence-grounded, and aligned with local requirements.
Translyx was founded to address that gap. The team combines decades of collective experience across in vitro diagnostics, laboratory medicine, clinical implementation, and healthcare supply. We identify globally validated innovations — including authorised digital pathology AI partner solutions — and introduce them to healthcare providers across hospital, community, and research settings.
Translyx works with Privexa Limited to bring protected AI software into healthcare, diagnostics, research, and evidence workflows. Privexa builds the software layer; Translyx focuses on clinical positioning, diagnostic adoption, local partnerships, and healthcare implementation.
Focus areas
Diagnostic Technology
AMR, sepsis, POCT, endocrinology, cardiac markers, oncology biomarkers, and precision medicine
Digital Pathology AI
Authorised Aiforia partner for clinical, preclinical, and research pathology in New Zealand
Governed Clinical AI
Reviewer-gated evidence workflows, field-level AI data protection, and privacy-first software
Regional Reach
New Zealand national, expanding into Australia and Pacific Island markets
Product ecosystem
Diagnostics, digital pathology AI, and governed software — connected for clinical impact
Translyx brings clinical technology into healthcare settings. Privexa builds the privacy-first software products that power those workflows.
Clinical technology company
Translyx Limited
Clinical technology, diagnostics, and healthcare adoption · Auckland, New Zealand
Authorised partner
Aiforia Digital Pathology AI
AI-assisted digital pathology for clinical, preclinical, and research workflows.
Built by Privexa
Privexa-Built AI Products
Privacy-first AI software for healthcare workflows — clinically positioned through Translyx.
Diagnostic portfolio
Clinical & Diagnostic Pipeline
AMR, sepsis, POCT, oncology, endocrine, cardiac, and precision medicine for New Zealand.
Translyx focuses on clinical positioning, diagnostic adoption, and local partnerships. Privexa builds the protected AI software layer. Together, they connect diagnostics, digital pathology AI, and governed software for regulated clinical environments.
Product portfolio
One clinical technology company. Multiple governed products. One diagnostic mission.
Aiforia Digital Pathology AI
Authorised partner solution represented by Translyx in New Zealand
Privexa AI Wrapper
Secure LLM gateway for privacy-preserving AI use
Privexa Cloud Shield
Field-level protection for cloud platforms and data workflows
Privexa Scribe
Privacy-protected clinical documentation and structured notes
Privexa Trace
Reviewer-gated evidence and synthetic control workflows
ClinicalTriage
Clinical pathway and referral grading support for authorised healthcare teams
Governance by design
Governed AI workflows — not AI with governance bolted on
Reviewer gates, visible limitations, and traceable outputs are structural features of how Privexa-built products operate — not disclaimers added after the fact.
Reviewer gate
Mandatory human sign-off before any synthetic analysis is generated. Governance stays in the workflow.
Full lineage
Every decision, dataset choice, and workflow stage remains traceable end-to-end.
Field-level protection
Sensitive clinical data can be transformed into protected placeholders before configured AI systems, cloud workflows, or approved processing layers receive it.
Visible limitations
Residual assumptions, workflow boundaries, and regulatory context remain visible — not hidden behind a polished output.
Privexa-built software
Protected AI software, delivered through a clinical technology lens
Translyx works with Privexa Limited to bring protected AI software into healthcare, diagnostics, research, and evidence workflows. Privexa builds the software layer — including AI Wrapper, Cloud Shield, Scribe, and Trace. Translyx focuses on clinical positioning, diagnostic adoption, local partnerships, and healthcare implementation.
Who Translyx works with
Hospitals & Laboratories
Diagnostic adoption, digital pathology, and clinical AI integration
Pathology Groups
AI-assisted scoring, quantitative outputs, and standardised workflows
Research Teams
Governed evidence workflows, synthetic control arms, and model development
Pharma & CROs
Reviewer-gated evidence packaging and submission-oriented workflows
Health Innovation Teams
Clinical AI evaluation, privacy-preserving deployment, and governance
Talk to Translyx about your clinical technology priorities
Whether the focus is diagnostic product evaluation, digital pathology AI, AI data protection, or reviewer-gated evidence workflows — the Translyx team can help you identify the right fit for your organisation.